Harvard Apparatus Regenerative (HART) 6.78 $HART
Harvard Apparatus Regenerative Technology CEO David Green Interviewed on Boston's CBS-TV Affiliate on May 8
Business Wire - Mon May 12, 6:30AM CDT
David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was interviewed by health reporter Dr. Mallika Marshall in a segment during the evening news on the CBS-TV affiliate in Boston (WBZ-TV).
Harvard Apparatus Regenerative Technology Reports Operating Results for First Quarter Ended March 31, 2014
Business Wire - Thu May 08, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today reported unaudited financial results for the three months ended March 31, 2014, the Company's first quarter of 2014.
Harvard Apparatus Regenerative Technology Schedules Release of First Quarter 2014 Financial Results and Investor Teleconference for May 8th
Business Wire - Thu May 01, 6:31AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its first quarter ended March 31, 2014 before market trading hours on Thursday, May 8, 2014. A conference call to discuss the company's first quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
Harvard Apparatus Regenerative Technology Names Saverio La Francesca, MD as its Chief Medical Officer
Business Wire - Wed Apr 16, 8:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has hired Saverio La Francesca, MD, a veteran cardiothoracic surgeon and leading organ transplant physician, as the Company's first Chief Medical Officer, effective April 14.
Harvard Apparatus Regenerative Technology Collaborator Successfully Transplants Regenerated Esophagus into Rat
Business Wire - Tue Apr 15, 11:23AM CDT
--Research to Be Presented at the American Association for Thoracic Surgery (AATS) Annual Meeting 2014 in Toronto
I’m Selling Harvard Biosciences
Jim Royal, The Motley Fool - Motley Fool - Thu Mar 27, 3:31PM CDT
My Special Situations portfolio took a stake in Harvard Bioscience before its recently completed spinoff of Harvard Apparatus Regenerative Technology . That was in January of last year, and the combined position has risen about 39%. Not bad....
Harvard Apparatus Regenerative Technology CEO David Green Interviewed on Bloomberg Television
Business Wire - Thu Mar 27, 6:00AM CDT
David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was interviewed on Bloomberg TV's "Market Makers" program on March 26.
Harvard Apparatus Regenerative Technology Spotlighted by Fast Company Co.Exist
Business Wire - Fri Mar 21, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Fast Company Co.Exist on March 19.
Harvard Apparatus Regenerative Technology Posts Updated Investor Presentation on Its Website
Business Wire - Fri Mar 14, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has posted an updated version of its investor presentation on its website.
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Year Ended December 31, 2013 Operating Results
Business Wire - Fri Mar 07, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today reported unaudited financial results for the three months and year ended December 31, 2013.
Harvard Apparatus Regenerative Technology Schedules Release of Fourth Quarter and Year-End 2013 Financial Results and Investor Teleconference for March 7th
Business Wire - Mon Mar 03, 12:45PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its fourth quarter and year ended December 31, 2013 before market trading hours on Friday, March 7, 2014. A conference call to discuss the company's fourth quarter and year-end results is scheduled for that same day at 11:00 AM (Eastern Time).
Harvard Apparatus Regenerative Technology to Present at 2nd Annual Regen Med Investor Day in New York City
Business Wire - Thu Feb 27, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at the 2nd Annual Regen Med Investor Day in New York City on March 26, 2014. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
Harvard Apparatus Regenerative Technology Collaboration with Texas Heart Institute Profiled by Houston's NBC-TV Affiliate on February 19
Business Wire - Wed Feb 26, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured February 19 in a television segment and article reported by the NBC-TV affiliate in Houston (KPRC-TV).
Harvard Apparatus Regenerative Technology Profiled by Xconomy.com
Business Wire - Mon Feb 24, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Xconomy.com on February 18.
Harvard Apparatus Regenerative Technology Spotlighted by Investor's Business Daily
Business Wire - Wed Feb 05, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was spotlighted in an article published by Investor's Business Daily on February 3.
Harvard Apparatus Regenerative Technology Profiled by MIT Technology Review
Business Wire - Fri Jan 17, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by MIT Technology Review on January 16.
Harvard Apparatus Regenerative Technology To Present at Biotech Showcase 2014 and OneMedForum 2014 in San Francisco
Business Wire - Tue Jan 07, 5:59AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at Biotech Showcase(TM) 2014 and OneMedForum 2014, both in San Francisco, on January 13, 2014. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
Harvard Apparatus Regenerative Technology Files Pre-IND Meeting Documents and Orphan Biologics Application with U.S. Food and Drug Administration
Business Wire - Mon Jan 06, 5:59AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has filed its pre-Investigational New Drug (IND) meeting documents with the U.S. Food and Drug Administration (FDA). The company expects the pre-IND meeting to take place by the end of January 2014.
Harvard Apparatus Regenerative Technology Profiled by Boston's ABC-TV Affiliate on November 27
Business Wire - Mon Dec 02, 10:50AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, was featured November 27 in a television segment and article reported by the ABC-TV affiliate in Boston (WCVB-TV).
Harvard Apparatus Regenerative Technology Profiled by Boston Globe and WBZ-AM CBS NewsRadio Boston
Business Wire - Thu Nov 21, 6:05AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, was featured recently in the Boston Globe and in a radio report and article from WBZ-AM CBS NewsRadio Boston.
Harvard Apparatus Regenerative Technology CEO David Green Interviewed on Boston's CBS-TV Affiliate on May 8
Business Wire - Mon May 12, 6:30AM CDT
David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was interviewed by health reporter Dr. Mallika Marshall in a segment during the evening news on the CBS-TV affiliate in Boston (WBZ-TV).
Harvard Apparatus Regenerative Technology Reports Operating Results for First Quarter Ended March 31, 2014
Business Wire - Thu May 08, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today reported unaudited financial results for the three months ended March 31, 2014, the Company's first quarter of 2014.
Harvard Apparatus Regenerative Technology Schedules Release of First Quarter 2014 Financial Results and Investor Teleconference for May 8th
Business Wire - Thu May 01, 6:31AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its first quarter ended March 31, 2014 before market trading hours on Thursday, May 8, 2014. A conference call to discuss the company's first quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
Harvard Apparatus Regenerative Technology Names Saverio La Francesca, MD as its Chief Medical Officer
Business Wire - Wed Apr 16, 8:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has hired Saverio La Francesca, MD, a veteran cardiothoracic surgeon and leading organ transplant physician, as the Company's first Chief Medical Officer, effective April 14.
Harvard Apparatus Regenerative Technology Collaborator Successfully Transplants Regenerated Esophagus into Rat
Business Wire - Tue Apr 15, 11:23AM CDT
--Research to Be Presented at the American Association for Thoracic Surgery (AATS) Annual Meeting 2014 in Toronto
I’m Selling Harvard Biosciences
Jim Royal, The Motley Fool - Motley Fool - Thu Mar 27, 3:31PM CDT
My Special Situations portfolio took a stake in Harvard Bioscience before its recently completed spinoff of Harvard Apparatus Regenerative Technology . That was in January of last year, and the combined position has risen about 39%. Not bad....
Harvard Apparatus Regenerative Technology CEO David Green Interviewed on Bloomberg Television
Business Wire - Thu Mar 27, 6:00AM CDT
David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was interviewed on Bloomberg TV's "Market Makers" program on March 26.
Harvard Apparatus Regenerative Technology Spotlighted by Fast Company Co.Exist
Business Wire - Fri Mar 21, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Fast Company Co.Exist on March 19.
Harvard Apparatus Regenerative Technology Posts Updated Investor Presentation on Its Website
Business Wire - Fri Mar 14, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has posted an updated version of its investor presentation on its website.
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Year Ended December 31, 2013 Operating Results
Business Wire - Fri Mar 07, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today reported unaudited financial results for the three months and year ended December 31, 2013.
Harvard Apparatus Regenerative Technology Schedules Release of Fourth Quarter and Year-End 2013 Financial Results and Investor Teleconference for March 7th
Business Wire - Mon Mar 03, 12:45PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its fourth quarter and year ended December 31, 2013 before market trading hours on Friday, March 7, 2014. A conference call to discuss the company's fourth quarter and year-end results is scheduled for that same day at 11:00 AM (Eastern Time).
Harvard Apparatus Regenerative Technology to Present at 2nd Annual Regen Med Investor Day in New York City
Business Wire - Thu Feb 27, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at the 2nd Annual Regen Med Investor Day in New York City on March 26, 2014. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
Harvard Apparatus Regenerative Technology Collaboration with Texas Heart Institute Profiled by Houston's NBC-TV Affiliate on February 19
Business Wire - Wed Feb 26, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured February 19 in a television segment and article reported by the NBC-TV affiliate in Houston (KPRC-TV).
Harvard Apparatus Regenerative Technology Profiled by Xconomy.com
Business Wire - Mon Feb 24, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Xconomy.com on February 18.
Harvard Apparatus Regenerative Technology Spotlighted by Investor's Business Daily
Business Wire - Wed Feb 05, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was spotlighted in an article published by Investor's Business Daily on February 3.
Harvard Apparatus Regenerative Technology Profiled by MIT Technology Review
Business Wire - Fri Jan 17, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by MIT Technology Review on January 16.
Harvard Apparatus Regenerative Technology To Present at Biotech Showcase 2014 and OneMedForum 2014 in San Francisco
Business Wire - Tue Jan 07, 5:59AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at Biotech Showcase(TM) 2014 and OneMedForum 2014, both in San Francisco, on January 13, 2014. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
Harvard Apparatus Regenerative Technology Files Pre-IND Meeting Documents and Orphan Biologics Application with U.S. Food and Drug Administration
Business Wire - Mon Jan 06, 5:59AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has filed its pre-Investigational New Drug (IND) meeting documents with the U.S. Food and Drug Administration (FDA). The company expects the pre-IND meeting to take place by the end of January 2014.
Harvard Apparatus Regenerative Technology Profiled by Boston's ABC-TV Affiliate on November 27
Business Wire - Mon Dec 02, 10:50AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, was featured November 27 in a television segment and article reported by the ABC-TV affiliate in Boston (WCVB-TV).
Harvard Apparatus Regenerative Technology Profiled by Boston Globe and WBZ-AM CBS NewsRadio Boston
Business Wire - Thu Nov 21, 6:05AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, was featured recently in the Boston Globe and in a radio report and article from WBZ-AM CBS NewsRadio Boston.
